US Broker Ratings

Danaher Corporation (DHR) Stock Analysis: Strong Buy Ratings with a 22% Upside Potential

Danaher Corporation (NYSE: DHR), a key player in the Healthcare sector, continues to capture investor interest with its robust market presence and potential for growth. With a market capitalization of..

McKesson Corporation (MCK) Stock Analysis: A Healthcare Giant with Steady Growth and Modest Upside

Investors might find McKesson Corporation (NYSE: MCK) an intriguing prospect given its commanding presence in the healthcare sector, particularly in medical distribution. With a market capitalization of $117.09 billion, McKesson..

HCA Healthcare, Inc. (HCA) Stock Analysis: A 5.35% Potential Upside Amid Strong Revenue Growth

HCA Healthcare, Inc. (NYSE: HCA) stands at the forefront of the U.S. healthcare sector, commanding a formidable presence with its vast network of medical care facilities. With a market capitalization..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Insights on Growth Potential and Analyst Ratings

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a formidable player in the biotechnology sector, focusing primarily on innovative therapies for cystic fibrosis (CF) and expanding its pipeline across various therapeutic..

Pfizer, Inc. (PFE) Stock Analysis: Navigating a 5.48% Potential Upside Amidst a Robust Dividend Yield

Pfizer, Inc. (NYSE: PFE), a cornerstone of the healthcare sector and renowned for its biopharmaceutical prowess, remains a focal point for investors eyeing stability coupled with potential growth. With a..

Thermo Fisher Scientific Inc (TMO) Stock Analysis: Exploring a 22.77% Upside Potential

Thermo Fisher Scientific Inc (NYSE: TMO), a prominent player in the healthcare sector, continues to capture investor interest with its robust market cap of $203.95 billion and an impressive 22.77%..

Amgen Inc. (AMGN) Stock Analysis: Navigating Healthcare Growth with a Robust Pipeline and a Promising Dividend Yield

Amgen Inc. (NASDAQ: AMGN), a titan in the healthcare sector, is a name synonymous with innovation and stability in the pharmaceutical industry. With a market capitalization of $207.15 billion, Amgen..

Verastem, Inc. (VSTM) Stock Analysis: Exploring the 164.73% Potential Upside in Biotech Innovation

Verastem, Inc. (NASDAQ: VSTM) is capturing the attention of investors with its promising potential upside of 164.73%, according to recent analyst ratings. This biopharmaceutical company, headquartered in Needham, Massachusetts, is..

Emergent BioSolutions (EBS) Stock Analysis: Exploring a 28% Potential Upside Amid Healthcare Innovations

Emergent BioSolutions Inc. (NYSE: EBS), renowned for its pivotal role in public health threat preparedness, is garnering attention from investors due to its notable 28.08% potential upside from its current..

Rapport Therapeutics, Inc. (RAPP) Investor Outlook: A 100% Upside Potential in Biotech Sector

Rapport Therapeutics, Inc. (NASDAQ: RAPP), a promising player in the biotechnology sector, is attracting attention with its ambitious focus on developing transformational small molecule medicines for central nervous system (CNS)..

Standard BioTools Inc. (LAB) Stock Analysis: Exploring the 25% Potential Upside Amid Market Challenges

Standard BioTools Inc. (NASDAQ: LAB) is a noteworthy player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $476.86 million, the company focuses on..

MBX Biosciences, Inc. (MBX) Stock Analysis: Biotech Innovator with 69.49% Potential Upside

MBX Biosciences, Inc. (MBX), a beacon of innovation in the healthcare sector, is capturing investor attention with its promising pipeline of precision peptide therapies. As a clinical-stage biopharmaceutical company, MBX..

Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Unpacking a 169.66% Potential Upside with Robust Revenue Growth

Investors eyeing the biotechnology sector may find Zevra Therapeutics, Inc. (NASDAQ: ZVRA) an intriguing proposition. This U.S.-based company, with a market capitalization of $470.65 million, is making significant strides in..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a Biotech Gem with Over 110% Upside Potential

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical-stage biopharmaceutical company, has captured the attention of investors with its promising pipeline of cancer therapies. Specializing in developing treatments to combat resistance mechanisms..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 49.91% Upside Potential for Investors

Castle Biosciences, Inc. (NASDAQ: CSTL), a dynamic player in the healthcare sector specializing in molecular diagnostics, is catching the attention of investors with its promising potential. Despite a recent dip..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 77% Upside Potential in the Biotech Sector

Oruka Therapeutics, Inc. (NASDAQ: ORKA), a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, is capturing investors’ attention with a significant potential upside of 77.17%, according to the latest analyst..

Precigen, Inc. (PGEN) Stock Analysis: Unpacking the 100% Upside Potential

In the ever-evolving world of biotechnology, Precigen, Inc. (NASDAQ: PGEN) stands out as a compelling player, particularly with its ambitious focus on gene and cell therapies targeting critical health issues..

Abivax SA (ABVX) Stock Analysis: Eyeing a 37.93% Potential Upside, All Eyes on Phase 3 Trials

Abivax SA (ABVX), a Paris-based biotechnology firm, is capturing significant investor interest with its promising drug pipeline and a compelling 37.93% potential upside. While the company is still in its..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Exploring a 44.67% Potential Upside in the Pediatric Orthopedic Market

OrthoPediatrics Corp. (NASDAQ: KIDS) represents a unique player in the healthcare sector, specifically within the medical devices industry. This Indiana-based company is dedicated to addressing the orthopedic needs of children,..

Inventiva S.A. (IVA) Stock Analysis: Exploring a 166.96% Potential Upside with Exciting Biotech Developments

Inventiva S.A. (IVA), a dynamic player in the biotechnology sector, is capturing investor attention with its cutting-edge pursuits in treating metabolic and rare diseases. Headquartered in Daix, France, Inventiva focuses..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds